{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:52:13Z","timestamp":1760233933271,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Purulent meningitis (PM) is a severe disease, characterized by high mortality and a formation of a residual neurological deficit. Loss of treatment of PM leads to the lethal outcome in 100% of cases. In addition, death and the development of residual neurological complications are possible despite adequate therapy. The aim of the study was to evaluate the cerebroprotective effects of a new pharmacological compound 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid (EMHDPA) on the bacterial purulent meningitis in a model of experimental pneumococcal meningitis. Meningitis was simulated by intrathecal injection of the suspension containing Streptococcus pneumoniae at the concentration of 5 \u00d7 109 CFU\/mL. The cerebroprotective effect was evaluated by survival rates, the severity of neurological deficit, investigatory behaviors, and results of short-term and long-term memory tests. The group administered with EMHDPA showed high survival rates, 80%. Animals treated with the studied compound showed a higher clinical assessment of the rat health status and specific force, and a lesser intensity of neurological deficit compared to the control group (p &lt; 0.05). Locomotor activity of the animals treated with EMHDPA was significantly higher compared to the control group (p &lt; 0.05). There is a decrease in the activity of all estimated indicators of oxidative stress in the group administered with 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid relative to the control group: a decrease in the activity of catalase\u201417%, superoxide dismutase\u201434%, malondialdehyde and acetylhydroperoxides\u201450%, and nitric oxide\u201485% (p &lt; 0.05). Analysis of the data obtained during the experiment leads to the conclusion about the effectiveness of 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid in the treatment of the experimental PM.<\/jats:p>","DOI":"10.3390\/biomedicines9030285","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T05:38:22Z","timestamp":1615441102000},"page":"285","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-2696","authenticated-orcid":false,"given":"Alina","family":"Agarkova","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, 308015 Belgorod, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Pokrovskii","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, 308015 Belgorod, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Kolesnichenko","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, 308015 Belgorod, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Gureev","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, 308015 Belgorod, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Gudyrev","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, 308015 Belgorod, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-9860","authenticated-orcid":false,"given":"Anna","family":"Peresypkina","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, 308015 Belgorod, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladislav","family":"Soldatov","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, 308015 Belgorod, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3822-4213","authenticated-orcid":false,"given":"Arkadii","family":"Nesterov","sequence":"additional","affiliation":[{"name":"Department of Pathology, Belgorod State National Research University, 308015 Belgorod, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Denisyuk","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Kursk State Medical University, 305000 Kursk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Korokin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University, 308015 Belgorod, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/B978-0-7020-4088-7.00093-6","article-title":"Bacterial meningitis","volume":"121","author":"Heckenberg","year":"2014","journal-title":"Handbook Clin. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(12)61187-8","article-title":"Effect of vaccines on bacterial meningitis worldwide","volume":"380","author":"McIntyre","year":"2012","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.31631\/2073-3046-2016-15-5-6-13","article-title":"Epidemiologica laspects of pneumococcal meningitis in the Russian Federation","volume":"15","author":"Koroleva","year":"2016","journal-title":"Epidemiol. Vaccinal Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.cmi.2016.01.007","article-title":"ESCMID guideline: Diagnosis and treatment of acute bacterial meningitis","volume":"22","author":"Cabellos","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_5","unstructured":"National Association of Specialists in Healthcare Associated Infections (NASKI) (2019, October 30). The Current Situation of Pneumococcal Infections in the World and in the Russian Federation. Available online: http:\/\/nasci.ru.Russian."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.31631\/2073-3046-2018-17-3-63-67","article-title":"Pneumococcal meningitis in adults: Clinical, epidemiological and diagnostic aspects","volume":"17","author":"Elistratova","year":"2018","journal-title":"Epidemiol. Vaccin."},{"key":"ref_7","first-page":"90","article-title":"Some clinical features of bacterial infections with purulent meningitis syndrome","volume":"111","author":"Shishov","year":"2011","journal-title":"Zhurn. Nevropatol. Psikhiatrii"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.31631\/2073-3046-2015-14-2-60-65","article-title":"Actuality of vaccination against pneumococcal infection for children in Krasnoyarsk","volume":"14","author":"Martynova","year":"2015","journal-title":"Epidemiol. Vaccinal Prev."},{"key":"ref_9","unstructured":"Skripchenko, N.V. (2015). Neuroinfections in Children, Tactic Studio."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(11)60580-1","article-title":"5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: A double-blind randomised equivalence study","volume":"377","author":"Molyneux","year":"2011","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(12)61185-4","article-title":"Dilemmas in the diagnosis of acute community-acquired bacterial meningitis","volume":"380","author":"Brouwer","year":"2012","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/QCO.0b013e328337f49e","article-title":"New understandings on the pathophysiology of bacterial meningitis","volume":"23","author":"Koedel","year":"2010","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2010.04.072","article-title":"Antibiotic therapy prevents, in part, the oxidative stress in the rat brain after meningitis induced by Streptococcus pneumoniae","volume":"478","author":"Barichello","year":"2010","journal-title":"Neurosci. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1128\/AAC.00148-13","article-title":"AdjunctiveN-Acetyl-l-Cysteine in Treatment of Murine Pneumococcal Meningitis","volume":"57","author":"Demel","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1212\/WNL.0b013e31827595f7","article-title":"Dexamethasone and long-term survival in bacterial meningitis","volume":"79","author":"Fritz","year":"2012","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Brouwer, M., McIntyre, P., Prasad, K., and van de Beek, D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev., 2015.","DOI":"10.1002\/14651858.CD004405.pub5"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3109\/00365548.2014.887223","article-title":"Dexamethasone treatment and prognostic factors in community-acquired bacterial meningitis: A Danish retrospective population-based cohort study","volume":"46","author":"Bodilsen","year":"2014","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(10)70023-5","article-title":"Adjunctive dexamethasone in bacterial meningitis: A meta-analysis of individual patient data","volume":"9","author":"Farrar","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_19","first-page":"3","article-title":"Studyngs some pharmacological effects of new 3-hydroxypyridine derivative","volume":"79","author":"Yasnetsov","year":"2016","journal-title":"Eksp Klin. Farmakol."},{"key":"ref_20","first-page":"434","article-title":"Pioneer of antioxidant neuroprotection 20 years","volume":"24","author":"Voronina","year":"2016","journal-title":"Clin. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.trsl.2013.12.008","article-title":"Erythropoietin prevents cognitive impairment and oxidative parameters in Wistar rats subjected to pneumococcal meningitis","volume":"163","author":"Barichello","year":"2014","journal-title":"Transl. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1535370213508354","article-title":"Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment caused by pneumococcal meningitis in Wistar rats","volume":"239","author":"Barrichello","year":"2014","journal-title":"Exp. Biol. Med."},{"key":"ref_23","first-page":"1365","article-title":"Factors influencing neurological outcome of children with bacterial meningitis at the emergency department","volume":"171","author":"Bargui","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11011-012-9315-9","article-title":"Antioxidant treatment prevents cognitive impairment and oxidative damage in pneumococcal meningitis survivor rats","volume":"27","author":"Barichello","year":"2012","journal-title":"Metab. Brain Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.00008-11","article-title":"Pathogenesis and Pathophysiology of Pneumococcal Meningitis","volume":"24","author":"Geldhoff","year":"2011","journal-title":"Clin. Microbiol. Rev."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/3\/285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:33:55Z","timestamp":1760160835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/3\/285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["biomedicines9030285"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9030285","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2021,3,11]]}}}